Skip to main content

Advertisement

SpringerLink
Log in

Sarcopenia is associated with survival in patients with urothelial carcinoma treated with systemic chemotherapy

  • Original Article
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

Background

Sarcopenia impacts perioperative outcomes and prognosis in various carcinomas. We aimed to investigate whether sarcopenia at the time of chemotherapy induction in patients with urothelial carcinoma is associated with prognosis.

Methods

We evaluated patients treated with chemotherapy for urothelial carcinoma between April 2013 and February 2018 at our institution and affiliated centers. Skeletal muscle mass (total psoas muscle, paraspinal muscle, and total skeletal muscle areas) were used to calculate the total psoas muscle index, paraspinal muscle index, and skeletal muscle index. All participants were grouped as per cutoff points set at the median value for each sex. Overall survival was evaluated using Cox regression analysis.

Results

Of the 240 patients, 171 were men and 69 were women; mean age during chemotherapy was 71 years (range: 43–88); and 36, 56, and 148 patients were at stages II, III, and IV, respectively. Paraspinal muscle index was most associated with the prognosis; groups with lower paraspinal muscle index were defined as sarcopenic (men: ≤ 20.9 cm2/m2, women: ≤ 16.8 cm2/m2). The overall survival was significantly longer in the non-sarcopenia group including all stages (p = 0.001), and in stage III (p = 0.048) and IV (p = 0.005) patients. There was no significant difference among stage II patients (p = 0.648). After propensity score matching, survival was still significantly longer in the non-sarcopenia group (p = 0.004).

Conclusions

Paraspinal muscle index measurements obtained during chemotherapy induction for urothelial carcinoma were independent prognostic factors. The absence of sarcopenia may lead to long-term survival in patients undergoing chemotherapy for urothelial carcinoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Hori M, Matsuda T, Shibata A et al (2015) Cancer incidence and incidence rates in Japan in 2009: a study of 32 population-based cancer registries for the Monitoring of Cancer Incidence in Japan (MCIJ) project. Jpn J Clin Oncol 45(9):884–891. https://doi.org/10.1093/jjco/hyv088

    Article  PubMed  Google Scholar 

  2. von der Maase H, Sengelov L, Roberts JT et al (2005) Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 23(21):4602–4608. https://doi.org/10.1200/JCO.2005.07.757

    Article  CAS  PubMed  Google Scholar 

  3. DeGeorge KC, Holt HR, Hodges SC (2017) Bladder cancer: diagnosis and treatment. Am Fam Physician 96(8):507–514

    PubMed  Google Scholar 

  4. Leow JJ, Chong YL, Chang SL et al (2021) Neoadjuvant and adjuvant chemotherapy for upper tract urothelial carcinoma: a 2020 systematic review and meta-analysis, and future perspectives on systemic therapy. Eur Urol 79(5):635–654. https://doi.org/10.1016/j.eururo.2020.07.003

    Article  CAS  PubMed  Google Scholar 

  5. Imamura CK (2015) Dose optimization of anticancer drugs in the elderly. Gan To Kagaku Ryoho 42(1):21–25

    PubMed  Google Scholar 

  6. Rosenberg IH (1997) Sarcopenia: origins and clinical relevance. J Nutr 127(5 Suppl):990S-991S. https://doi.org/10.1093/jn/127.5.990S

    Article  CAS  PubMed  Google Scholar 

  7. von Haehling S, Morley JE, Anker SD (2010) An overview of sarcopenia: facts and numbers on prevalence and clinical impact. J Cachexia Sarcopenia Muscle 1(2):129–133. https://doi.org/10.1007/s13539-010-0014-2

    Article  Google Scholar 

  8. Yumioka T, Honda M, Nishikawa R et al (2020) Sarcopenia as a significant predictive factor of neutropenia and overall survival in urothelial carcinoma patients underwent gemcitabine and cisplatin or carboplatin. Int J Clin Oncol 25(1):158–164. https://doi.org/10.1007/s10147-019-01544-5

    Article  CAS  PubMed  Google Scholar 

  9. Fearon K, Strasser F, Anker SD et al (2011) Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 12(5):489–495. https://doi.org/10.1016/S1470-2045(10)70218-7

    Article  PubMed  Google Scholar 

  10. Austin PC (2011) Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat 10(2):150–161. https://doi.org/10.1002/pst.433

    Article  PubMed  Google Scholar 

  11. Inouye SK, Studenski S, Tinetti ME et al (2007) Geriatric syndromes: clinical, research, and policy implications of a core geriatric concept. J Am Geriatr Soc 55(5):780–791. https://doi.org/10.1111/j.1532-5415.2007.01156.x

    Article  PubMed  PubMed Central  Google Scholar 

  12. Cruz-Jentoft AJ, Baeyens JP, Bauer JM et al (2010) Sarcopenia: European consensus on definition and diagnosis: report of the European Working Group on Sarcopenia in Older People. Age Ageing 39(4):412–423. https://doi.org/10.1093/ageing/afq034

    Article  PubMed  PubMed Central  Google Scholar 

  13. Lukaski H (1997) Sarcopenia: assessment of muscle mass. J Nutr 127(5 Suppl):994S-997S. https://doi.org/10.1093/jn/127.5.994S

    Article  CAS  PubMed  Google Scholar 

  14. Taguchi S, Akamatsu N, Nakagawa T et al (2016) Sarcopenia evaluated using the skeletal muscle index is a significant prognostic factor for metastatic urothelial carcinoma. Clin Genitourin Cancer 14(3):237–243. https://doi.org/10.1016/j.clgc.2015.07.015

    Article  PubMed  Google Scholar 

  15. Prado CM, Purcell SA, Alish C et al (2018) Implications of low muscle mass across the continuum of care: a narrative review. Ann Med 50(8):675–693. https://doi.org/10.1080/07853890.2018.1511918

    Article  PubMed  Google Scholar 

  16. Abe H, Takei K, Uematsu T et al (2018) Significance of sarcopenia as a prognostic factor for metastatic urothelial carcinoma patients treated with systemic chemotherapy. Int J Clin Oncol 23(2):338–346. https://doi.org/10.1007/s10147-017-1207-x

    Article  PubMed  Google Scholar 

  17. Fortin M, Battié MC (2012) Quantitative paraspinal muscle measurements: inter-software reliability and agreement using OsiriX and ImageJ. Phys Ther 92(6):853–864. https://doi.org/10.2522/ptj.20110380

    Article  PubMed  Google Scholar 

  18. Pinto Dos Santos D, Kloeckner R, Koch S et al (2020) Sarcopenia as prognostic factor for survival after orthotopic liver transplantation. Eur J Gastroenterol Hepatol 32(5):626–634. https://doi.org/10.1097/MEG.0000000000001552

    Article  CAS  PubMed  Google Scholar 

  19. Prado CM, Lieffers JR, McCargar LJ et al (2008) Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol 9(7):629–635. https://doi.org/10.1016/S1470-2045(08)70153-0

    Article  PubMed  Google Scholar 

  20. Psutka SP, Carrasco A, Schmit GD et al (2014) Sarcopenia in patients with bladder cancer undergoing radical cystectomy: impact on cancer-specific and all-cause mortality. Cancer 120(18):2910–2918. https://doi.org/10.1002/cncr.28798

    Article  PubMed  Google Scholar 

  21. Smith AB, Deal AM, Yu H et al (2014) Sarcopenia as a predictor of complications and survival following radical cystectomy. J Urol 191(6):1714–1720. https://doi.org/10.1016/j.juro.2013.12.047

    Article  PubMed  Google Scholar 

  22. Wan F, Zhu Y, Gu C et al (2014) Lower skeletal muscle index and early complications in patients undergoing radical cystectomy for bladder cancer. World J Surg Oncol 12:14. https://doi.org/10.1186/1477-7819-12-14

    Article  PubMed  PubMed Central  Google Scholar 

  23. Psutka SP, Boorjian SA, Moynagh MR et al (2015) Mortality after radical cystectomy: impact of obesity versus adiposity after adjusting for skeletal muscle wasting. J Urol 193(5):1507–1513. https://doi.org/10.1016/j.juro.2014.11.088

    Article  PubMed  Google Scholar 

  24. Hirasawa Y, Nakashima J, Yunaiyama D et al (2016) Sarcopenia as a novel preoperative prognostic predictor for survival in patients with bladder cancer undergoing radical cystectomy. Ann Surg Oncol 23(Suppl 5):1048–1054. https://doi.org/10.1245/s10434-016-5606-4

    Article  PubMed  Google Scholar 

  25. Miyake M, Morizawa Y, Hori S et al (2017) Clinical impact of postoperative loss in psoas major muscle and nutrition index after radical cystectomy for patients with urothelial carcinoma of the bladder. BMC Cancer 17(1):237. https://doi.org/10.1186/s12885-017-3231-7

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Miyake M, Morizawa Y, Hori S et al (2017) Integrative assessment of pretreatment inflammation-, nutrition-, and muscle-based prognostic markers in patients with muscle-invasive bladder cancer undergoing radical cystectomy. Oncology 93(4):259–269. https://doi.org/10.1159/000477405

    Article  PubMed  Google Scholar 

  27. Saitoh-Maeda Y, Kawahara T, Miyoshi Y et al (2017) A low psoas muscle volume correlates with a longer hospitalization after radical cystectomy. BMC Urol 17(1):87. https://doi.org/10.1186/s12894-017-0279-2

    Article  PubMed  PubMed Central  Google Scholar 

  28. Mayr R, Gierth M, Zeman F et al (2018) Sarcopenia as a comorbidity-independent predictor of survival following radical cystectomy for bladder cancer. J Cachexia Sarcopenia Muscle 9(3):505–513. https://doi.org/10.1002/jcsm.12279

    Article  PubMed  PubMed Central  Google Scholar 

  29. Ha YS, Kim SW, Kwon TG et al (2019) Decrease in skeletal muscle index 1 year after radical cystectomy as a prognostic indicator in patients with urothelial bladder cancer. Int Braz J Urol 45(4):686–694. https://doi.org/10.1590/S1677-5538.IBJU.2018.0530

    Article  PubMed  PubMed Central  Google Scholar 

  30. Ritch CR, Cookson MS, Clark PE et al (2019) Perioperative oral nutrition supplementation reduces prevalence of sarcopenia following radical cystectomy: results of a prospective randomized controlled trial. J Urol 201(3):470–477. https://doi.org/10.1016/j.juro.2018.10.010

    Article  PubMed  Google Scholar 

  31. Fukushima H, Nakanishi Y, Kataoka M et al (2016) Prognostic significance of sarcopenia in upper tract urothelial carcinoma patients treated with radical nephroureterectomy. Cancer Med 5(9):2213–2220. https://doi.org/10.1002/cam4.795

    Article  PubMed  PubMed Central  Google Scholar 

  32. Ishihara H, Kondo T, Omae K et al (2017) Sarcopenia predicts survival outcomes among patients with urothelial carcinoma of the upper urinary tract undergoing radical nephroureterectomy: a retrospective multi-institution study. Int J Clin Oncol 22(1):136–144. https://doi.org/10.1007/s10147-016-1021-x

    Article  CAS  PubMed  Google Scholar 

  33. Kocher NJ, Jafri S, Balabhadra S et al (2018) Is sarcopenia and sarcopenic obesity associated with clinical and pathological outcomes in patients undergoing radical nephroureterectomy? Urol Oncol 36(4):156.e117-156.e122. https://doi.org/10.1016/j.urolonc.2017.12.004

    Article  Google Scholar 

  34. Anno T, Kikuchi E, Fukumoto K et al (2018) Preoperative sarcopenia status is associated with lymphovascular invasion in upper tract urothelial carcinoma patients treated with radical nephroureterectomy. Can Urol Assoc J 12(3):E132–E136. https://doi.org/10.5489/cuaj.4786

    Article  PubMed  Google Scholar 

  35. Tsutsumi S, Kawahara T, Teranishi JI et al (2018) A low psoas muscle volume predicts longer hospitalization and cancer recurrence in upper urinary tract urothelial carcinoma. Mol Clin Oncol 8(2):320–322. https://doi.org/10.3892/mco.2017.1537

    Article  PubMed  Google Scholar 

  36. Itami Y, Miyake M, Tatsumi Y et al (2019) Preoperative predictive factors focused on inflammation-, nutrition-, and muscle-status in patients with upper urinary tract urothelial carcinoma undergoing nephroureterectomy. Int J Clin Oncol 24(5):533–545. https://doi.org/10.1007/s10147-018-01381-y

    Article  PubMed  Google Scholar 

  37. Mari A, D’Andrea D, Kimura S et al (2018) Sarcopenia as a predictive factor for response to upfront cisplatin-based chemotherapy in patients with muscle-invasive urothelial bladder cancer. Urol Int 101(2):197–200. https://doi.org/10.1159/000489013

    Article  CAS  PubMed  Google Scholar 

  38. Rimar KJ, Glaser AP, Kundu S et al (2018) Changes in lean muscle mass associated with neoadjuvant platinum-based chemotherapy in patients with muscle invasive bladder cancer. Bladder Cancer 4(4):411–418. https://doi.org/10.3233/BLC-180188

    Article  PubMed  PubMed Central  Google Scholar 

  39. Zargar H, Almassi N, Kovac E et al (2017) Change in psoas muscle volume as a predictor of outcomes in patients treated with chemotherapy and radical cystectomy for muscle-invasive bladder cancer. Bladder Cancer 3(1):57–63. https://doi.org/10.3233/BLC-160080

    Article  PubMed  PubMed Central  Google Scholar 

  40. Lyon TD, Frank I, Takahashi N et al (2019) Sarcopenia and response to neoadjuvant chemotherapy for muscle-invasive bladder cancer. Clin Genitourin Cancer 17(3):216-222.e215. https://doi.org/10.1016/j.clgc.2019.03.007

    Article  PubMed  Google Scholar 

  41. Fukushima H, Yokoyama M, Nakanishi Y et al (2015) Sarcopenia as a prognostic biomarker of advanced urothelial carcinoma. PLoS One 10(1):e0115895. https://doi.org/10.1371/journal.pone.0115895

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Kasahara R, Kawahara T, Ohtake S et al (2017) A low psoas muscle index before treatment can predict a poorer prognosis in advanced bladder cancer patients who receive gemcitabine and nedaplatin therapy. Biomed Res Int 2017:7981549. https://doi.org/10.1155/2017/7981549

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Fukushima H, Kataoka M, Nakanishi Y et al (2018) Posttherapeutic skeletal muscle mass recovery predicts favorable prognosis in patients with advanced urothelial carcinoma receiving first-line platinum-based chemotherapy. Urol Oncol 36(4):156.e159-156.e116. https://doi.org/10.1016/j.urolonc.2017.09.016

    Article  CAS  Google Scholar 

  44. Antoun S, Baracos VE, Birdsell L et al (2010) Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma. Ann Oncol 21(8):1594–1598. https://doi.org/10.1093/annonc/mdp605

    Article  CAS  PubMed  Google Scholar 

  45. Prado CM, Baracos VE, McCargar LJ et al (2007) Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity. Clin Cancer Res 13(11):3264–3268. https://doi.org/10.1158/1078-0432.CCR-06-3067

    Article  CAS  PubMed  Google Scholar 

  46. Cosquéric G, Sebag A, Ducolombier C et al (2006) Sarcopenia is predictive of nosocomial infection in care of the elderly. Br J Nutr 96(5):895–901. https://doi.org/10.1017/bjn20061943

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

The Authors would like to thank the doctors of satellite hospitals for their contribution in data collection.

Author information

Authors and Affiliations

  1. Division of Urology, Department of Surgery, Faculty of Medicine, Tottori University, 36-1, Nishicho, Yonago, Tottori, 683-8504, Japan

    Ryutaro Shimizu, Masashi Honda, Shogo Teraoka, Tetsuya Yumioka, Noriya Yamaguchi, Bunya Kawamoto, Hideto Iwamoto, Shuichi Morizane, Katsuya Hikita & Atsushi Takenaka

Authors
  1. Ryutaro Shimizu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Masashi Honda
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shogo Teraoka
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tetsuya Yumioka
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Noriya Yamaguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Bunya Kawamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hideto Iwamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Shuichi Morizane
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Katsuya Hikita
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Atsushi Takenaka
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ryutaro Shimizu.

Ethics declarations

Conflict of interest

The authors have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

The need for informed consent was waived because of the retrospective nature of the study.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Shimizu, R., Honda, M., Teraoka, S. et al. Sarcopenia is associated with survival in patients with urothelial carcinoma treated with systemic chemotherapy. Int J Clin Oncol 27, 175–183 (2022). https://doi.org/10.1007/s10147-021-02032-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-021-02032-5

Keywords

Search

Navigation